Published
March 7, 2024

Stats-GWAS

icon-benefit
In set up
HomeSubstudies
Stats-GWAS

SNAP-GWAS: An integrate precision medicine platform to predict antibiotic treatment outcomes in SNAP

We are inviting you to participate in this substudy because you have joined the SNAP platform.

  • A large amount of variation exists within the genome of pathogenic Staphylococcus aureus that can be observed between regions or even individuals. These genetic differences can affect how the pathogen interacts with the host and administered treatments.
  • These genetic differences could affect the optimal treatment regimen for any one individual with a Staphylococcus aureus bloodstream infection.
  • This study aims to use a computational approach to compare the genomes of different strains of S. aureus pathogens to identify markers that can be used to steer clinicians' decisions to the best possible treatment option at a targeted, individual level.

This study is being conducted worldwide using bacterial isolates collected from all sites.

Lead Investigator: Dr. Stefano Giulieri - University of Melbourne, The Peter Doherty Institute for Infection and Immunity.

Email: stefano.giulieri@unimelb.edu.au

What will the sub study involve - more information

Please read the below information to learn more about the assessments and tests involved in this sub-study:

  • Bacterial isolates: Baseline bloodstream isolates from persistent bactaraemia (5 days or longer) or recurrent infections within 90 days of enrolment will be collected.

We will use these isolates to perform whole genome sequencing and high-throughput antibiotic susceptibility testing.

Risks and benefits of taking part in this sub study

Risks:

  • There are no potential risks or adverse events that are expected to occur during this substudy

Benefits:

  • Data from this substudy will benefit the wider population of individuals affected with Staphylococcus aureus bloodstream infections.
  • Clinicians will be better informed to make decisions that optimizes the treatment of S. aureus bloodstream infections, potentially reducing treatment time, cost, and minimizing any adverse effects as a result of treatment.
Where will my information be collected and stored?
  • Your information will be kept strictly confidential
  • Bacterial isolates should already be available as they are collected as part of the core SNAP trial protocol
What if I withdraw from the substudy?

You can withdraw from the sub study and/or from future use of your samples at any time, just notify a member of the SNAP study team.

If you withdraw, we will keep any information we have collected about you up until you withdraw. If you do not agree with this, you should not join this substudy.

Substudies in Progress

SNAP Trial

CERT-SNAP

Combination Cefazolin with Ertapenem for methicillin-susceptible Staphylococcus aureus bacteremia.

icon-benefit
All Interested
icon-benefit
Substudy in Progress

DAPTO-SNAP

Daptomycin vs. Vancomycin for the Treatment of MRSA bacteremia

icon-benefit
All Interested
icon-benefit
Substudy in Progress

SABSI

Profiling the genetic and epigenetic determinants that predispose to severe manifestations of Staphylococcus aureus bacteremia

icon-benefit
All Interested
icon-benefit
Substudy in Progress

cfDNA

Cell-free DNA is a Versatile Analyte to Monitor Complications and Guide Treatment Duration in Staphylococcus aureus Bacteremia

icon-benefit
Any interested
icon-benefit
Substudy in Progress

SABSI-Outcomes

Derivation and Validation of Phenotypes of Staphylococcus aureus bloodstream infection, with Correlation with Outcome.

icon-benefit
Any Interested
icon-benefit
Substudy in Progress

PR-O-SNAP

PK/PD of oral beta-lactam with and without probenecid for treatment of Staphylococcus aureus bacteraemia.

icon-benefit
New Zealand
icon-benefit
Substudy in Progress
BACK TO TOP